Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue and Competitors
Estimated Revenue & Valuation
- Tonix Pharmaceuticals Holding Corp. (TNXP)'s estimated annual revenue is currently $32.2M per year.
- Tonix Pharmaceuticals Holding Corp. (TNXP)'s estimated revenue per employee is $201,000
Employee Data
- Tonix Pharmaceuticals Holding Corp. (TNXP) has 160 Employees.
- Tonix Pharmaceuticals Holding Corp. (TNXP) grew their employee count by 10% last year.
Tonix Pharmaceuticals Holding Corp. (TNXP)'s People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | EVP, Medical | Reveal Email/Phone |
4 | Head Talent Acquisition | Reveal Email/Phone |
5 | EVP Product Development | Reveal Email/Phone |
6 | EVP, Infectious Disease Research and Development | Reveal Email/Phone |
7 | EVP, Research | Reveal Email/Phone |
8 | EVP, Experimental Chemistry | Reveal Email/Phone |
9 | VP, Medical Affairs | Reveal Email/Phone |
10 | VP, Marketing | Reveal Email/Phone |
Tonix Pharmaceuticals Holding Corp. (TNXP) Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.1M | 65 | 7% | N/A | N/A |
#2 | $354.3M | 484 | -2% | $567.1M | N/A |
#3 | $347.1M | 1727 | -8% | N/A | N/A |
#4 | $8.8M | 44 | 13% | N/A | N/A |
#5 | $6M | 30 | 11% | N/A | N/A |
#6 | $46.6M | 232 | 4% | N/A | N/A |
#7 | $6.6M | 33 | -3% | N/A | N/A |
#8 | $11.3M | 56 | 12% | N/A | N/A |
#9 | $168.8M | 840 | 46% | N/A | N/A |
#10 | $12.3M | 61 | -21% | N/A | N/A |
What Is Tonix Pharmaceuticals Holding Corp. (TNXP)?
Tonix is developing innovative pharmaceutical products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine. Further information about Tonix can be found at www.tonixpharma.com.
keywords:N/A
N/A
Total Funding
160
Number of Employees
$32.2M
Revenue (est)
10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Tonix Pharmaceuticals Holding Corp. (TNXP) News
CHATHAM, N.J., April 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical...
They set a sell rating on the stock. Several institutional investors have recently bought and sold shares of TNXP. Royal Bank of Canada...
... of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) increased by over 3% pre-market today. Investors are responding positively to Tonix...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $47.5M | 160 | 23% | N/A |
#2 | $24.6M | 160 | -5% | N/A |
#3 | $24.1M | 160 | -12% | $270.9M |
#4 | $175.5M | 160 | -57% | $365.9M |
#5 | $36.1M | 160 | 25% | N/A |